Background-There are limited data on the frequency of and factors associated with quantitative coronary angiography (QCA)-defined longitudinal stent deformation (LSD) in various contemporary drug-eluting stents platforms. This study sought to evaluate the predictors of LSD and its long-term clinical implication. Methods and Results-A patient-level pooled analysis was performed with 7350 lesions in 5871 patients treated with platinum-chromium-based everolimus-eluting stent (Promus Element), cobalt-chromium-based everolimus-eluting stent (Promus/Xience V), or cobalt-chromium-based zotarolimus-eluting stent (Endeavor Resolute). QCA was performed to analyze differences of stent length between immediate post-deployment and final post-procedure. Independent factors associated with LSD were identified. Clinical outcomes at 3 years were compared between those with and without QCAbased LSD. The frequency of QCA-based LSD was 1.12% (82 cases). Nine of these cases were angiographically overt. Left main or ostial lesion, bifurcation treatment with provisional side branch stenting or ballooning, additional downstream intervention of a distal lesion, intravascular ultrasound use, and adjunctive post-dilatation were independently associated with QCA-based LSD. The type of stent was not associated with QCA-based LSD. Rates of target lesion failure were nominally higher in lesions with QCA-based LSD than in those without (8.97% versus 5.88%; hazard ratio, 1.415; 95% confidence interval, 0.631-3.175; P=0.399). Conclusions-LSD is uncommon with contemporary drug-eluting stents, regardless of the type of stent platform. LSD is mainly associated with procedural factors, especially with additional downstream procedures which require the passage of devices through the stent. Careful manipulation of poststent imaging or procedural devices is required to prevent LSD. More data are needed to clarify the impact of LSD on clinical events. (Circ Cardiovasc Interv. 2017;10:e005518.
L
ongitudinal stent deformation (LSD) is a well-recognized complication of current drug-eluting stents (DES). [1] [2] [3] [4] [5] The Promus Element stent has been the most frequently reported DES that is vulnerable to LSD, mainly because of its weakness against longitudinal forces which may be explained by its thin strut and offset peak-to-peak design.
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In addition to the Element platform, LSD has been reported with other DES, suggesting that risk factors outside of stent platform design may have a role in LSD. [4] [5] [6] [7] The location or complexity of lesion, mechanical effect of extra backup guiding catheter, and secondary devices such as postdilation balloons and intravascular ultrasound (IVUS) catheters were considered to be significantly related with LSD. 4, 5, 8, 9 However, there are several short comings with these studies. First, reports have mostly been anecdotal, without a comprehensive systematic analysis including clinical, lesion, and procedural characteristics in various stent platforms. Second, most of the studies did not specify a standard definition of LSD. 4 Thus, there is paucity of data on major predictors and clinical significance of LSD defined by quantitative methods. Furthermore, the long-term clinical implication of LSD beyond 1-year follow-up such as late catchup or very late stent thrombosis has been unclear. We sought to evaluate independent predictors of quantitative coronary angiography (QCA)-defined LSD and its impact on long-term clinical outcomes from a large multicenter database.
Methods

Establishment of Patient-Level Pooled DES Cohort
Patient-level data were pooled from 2 nationwide multicenter studies, 1 randomized trial and 1 registry, covering a total of 9299 lesions in 6811 patients treated with platinum-chromium-based everolimuseluting stent (Promus Element; Boston Scientific, Maple Grove, MN), cobalt-chromium-based everolimus-eluting stent (Promus or Xience V; Abbott Vascular, Santa Clara, CA), or cobalt-chromium-based zotarolimus-eluting stent (Endeavor Resolute; Medtronic, Minneapolis, MN). The HOST-ASSURE (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety and Effectiveness of Drug-Eluting Stents and Antiplatelet Regimen) was a prospective, randomized, multicenter trial in South Korea. The detailed study design, eligibility criteria, and 1-year outcome were published previously. 10, 11 In brief, the study had a 2×2 factorial design, in which randomization was performed for the type of DES (platinum-chromium-based everolimus-eluting stent versus cobalt-chromium-based zotarolimuseluting stent) and the type of 1-month intensified antiplatelet therapy followed by conventional dual antiplatelet therapy, during the period of 2010 through 2011. The EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) registry was a dedicated second-generation DES registry that enrolled all-comers treated with >1 everolimus-eluting stent (Xience V or Promus) without any exclusion criteria during the period of 2008 through 2010. 12 Therefore, the pooled sample size was 9299 lesions in 6811 patients enrolled from 50 participating centers in South Korea. The study protocol was approved by the ethics committee at each participating center and was conducted according to the principles of the Declaration of Helsinki. All patients provided written informed consent at enrollment to each trial or registry.
Interventional Procedures and Follow-Up
Percutaneous coronary intervention was performed according to standard techniques in line with current guidelines. Unless there was an undisputed reason for discontinuing dual antiplatelet therapy, all patients were advised to take aspirin (at least 100 mg/d) indefinitely and clopidogrel (75 mg/d) for the duration determined by the protocol of each study. After the index procedure, clinical follow-ups were performed at 1, 3, 6 or 9, 13, 24 and 36 months. Among the pooled population, 448 patients (6.6% of 6811 patients) were lost to follow-up. However, the vital status of these patients was completely assessed by using unique individual identification numbers of the Korean nationwide healthcare system. The clinical events that occurred within 3-year follow-up were analyzed, and the median follow-up duration was 1096 days (interquartile interval, 1068-1114 days).
Angiographic Analysis and Definition of LSD
Angiographic analysis of procedures was performed in all available and readable cases to identify LSD. Quantitative coronary analysis of angiographic images was performed at a central core laboratory (Seoul National University Hospital Cardiovascular Clinical Research Center Angiographic Core Laboratory) by specialized QCA technicians who were completely blinded to the contents and purpose of this study. The Cardiovascular Angiography Analysis System 5.7 QCA system (Pie Medical Imaging, Maastricht, the Netherlands) was used for automated contour detection and quantification. We excluded 1939 lesions that lacked required angiographic images to accurately measure stent length or were unassessable because of stent overlap. First, a qualitative analysis was done to assess the presence of angiographically overt LSD. Angiographically overt LSD was defined as any inconsistency in the radiodensity pattern along the length of the stent or other gross irregularities or deformities. To quantitatively assess stent deformation, the relative and absolute differences of stent length between immediate post-deployment and final post-procedure were measured. Absolute difference >3 mm or relative difference >20% was defined as QCA-based LSD. After thorough review of all cases that were initially classified as LSD group, 10 cases of foreshortening or those did not use the same projection angle between immediate post-deployment
WHAT IS KNOWN
• Longitudinal stent deformation (LSD) has been reported previously as a potential complication of contemporary thin strut stents and was mostly reported in the Promus Element stent, but it has also been intermittently reported in other stent platforms, suggesting that there exist risk factors other than stent design for LSD.
• There are limited data on major predictors of LSD defined by quantitative methods, and the long-term clinical implication of LSD is unclear.
WHAT THE STUDY ADDS
• Any use of secondary device after stenting was the single most important independent factor related with quantitative coronary angiography-based LSD, regardless of the stent type or other lesion factors.
• Although the prognostic impact of quantitative coronary angiography-based LSD on 3-year clinical outcomes was statistically insignificant, there were numerically higher rates of target lesion failure in the quantitative coronary angiography-based LSD group.
• Careful manipulation of secondary imaging and procedure devices may decrease the incidence of LSD. 
Clinical End Points
The key clinical outcome target lesion failure (TLF; a composite of cardiac death, target vessel-related myocardial infarction, or a clinically indicated target lesion revascularization), and patient-oriented composite outcome (POCO; a composite of all-cause mortality, any myocardial infarction, and any repeat revascularization). A revascularization was considered clinically driven if angiography during follow-up showed a diameter stenosis ≥50% with at least one of the following: (1) history of recurrent angina pectoris, presumably related to the target vessel; (2) objective signs of ischemia at rest or during exercise test by electrocardiogram, presumably related to target vessel; (3) fractional flow reserve ≤0.80; or (4) a target lesion revascularization with a diameter stenosis ≥70% even in the absence of aforementioned ischemic signs or symptoms, according to the Academic Research Consortium definitions. 13 Other clinical outcomes included individual components of TLF and POCO, and stent thrombosis defined as definite or probable according to the Academic Research Consortium definitions. The independent clinical event adjudication committee, whose members were unaware of study group assignments, assessed all of clinical end points.
Statistical Analysis
Continuous variables were presented as mean and SD and compared using the Student t test. Categorical variables were presented as counts and percentages and compared using the χ 2 test. Difference between immediate postdeployment and final postprocedural stent lengths among 3 groups by stent platform was assessed by analysis of variance method and Student t test, as appropriate. Multivariable logistic regression analysis with stepwise selection method was used to identify clinical, lesion, stent-related, and procedural factors independently associated with the occurrence of QCA-based LSD. Variables used in adjustment were listed as follows: age, sex, diabetes mellitus, dyslipidemia, angiographic disease extent, left main lesion, ostial lesion, severe calcification, type B2 or C lesion, stent platform design (offset peak to peak, peak to peak, or peak to valley), adjunctive balloon angioplasty, IVUS or optical coherence tomography use, bifurcation treatment with side branch stenting or ballooning, and additional downstream intervention of a distal lesion. Variables were selected if they were significantly different between 2 groups (P value <0.1), or if they had clinical relevance. Results of regression were presented as odds ratio with 95% confidence intervals, and the Firth penalized likelihood method was used to calculate odds ratio and 95% confidence interval for comparison groups with no events in the reference group. 14 Cumulative event rates were estimated using the Kaplan-Meier method. Hazard ratios with 95% confidence interval were estimated using the marginal Cox proportional hazards method. The assumption of proportionality was examined using log-minus-log plot for each outcome. As angiographic data were composed of characteristics per lesion, a marginal regression model approach was used to adjust the effect of correlation between multiple lesions in 1 patient. 15 The consistency of effects of secondary device use on LSD was assessed using Cox regression models with tests for interaction in various subgroups by lesion location (left main artery or ostium), complexity of lesion (angulation, severe calcification, type B2 or C), and type of stent platform design. All P values were 2-sided, and a value <0.05 was considered statistically significant. Statistical analyses were performed using Stata statistical software release 12 (StataCorp, College Station, TX) and SPSS statistical package version 19.0 (SPSS Inc, Chicago, IL).
Results
Baseline Characteristics
Out of a total of 7350 lesions, 82 cases (1.12%) in 81 patients with QCA-based LSD were identified. Baseline demographic features, cardiovascular risk factors, and working diagnosis were similar between LSD and non-LSD group (Table 1) . The proportion of multivessel disease was higher in the LSD group. LSD group also had significantly higher proportion of lesions located in left main artery or ostium and lesions which were severely calcified. The type of stent platform design was evenly distributed (Table 2) . Among the procedural factors, the proportion of those who used any secondary device post-stenting, including post-dilatation, IVUS, side branch ballooning or provisional stenting, and additional downstream intervention, was significantly higher in LSD group. The prevalence of lesion-or procedure-related risk factors associated with the occurrence of LSD was summarized in Figure 2 .
Change of Stent Length During Procedures by Platform Designs
The QCA-based stent length difference between immediate post-deployment and final post-procedure are presented according to the 3 types of stent platform: offset peak-to-peak, peak-to-peak, and peak-to-valley designs in Figure 3 . For both relative ratio and absolute differences, there were no significant differences among the 3 groups (for ratio, analysis of variance P=0.927; for absolute difference, analysis of variance P=0.679).
The mean values of stent length ratio were between 0.999 and 1.000, and mean values of absolute difference varied within a very narrow range (−0.022 mm in offset peak-to-peak design, −0.059 mm in peak-to-peak design, −0.044 mm in peak-tovalley design). Representative cases of LSD in 3 different types of stent platforms are presented in Figure 4 and described in more detail in Figures I through III in the Data Supplement.
Factors Associated With the Occurrence of QCABased LSD
Factors independently associated with the occurrence of QCAbased LSD were identified by multivariable regression (Table 3) . Left main lesion and ostial lesion, bifurcation treatment with provisional side branch stenting or ballooning, additional downstream intervention, IVUS use, and adjunctive post-dilatation were independent predictors of QCA-based LSD. Stent design was not associated with QCA-based LSD. The effect of any secondary device use on the occurrence of QCA-based LSD was analyzed for various subgroups ( Figure 5 ). Strong associations with LSD were consistently observed across multiple subgroups irrespective of lesion location, complexity of lesions, and stent design, without any significant interaction.
Long-Term Outcomes According to the Presence of QCA-Based LSD
The 3-year clinical outcomes were not significantly different between those with and without QCA-based LSD (Table 4 ; Figure IV in the Data Supplement). Differences in cumulative incidence of TLF, POCO, and individual components CABG indicates coronary artery bypass grafting; CHF, congestive heart failure; CVA, cerebrovascular event; LSD, longitudinal stent deformation; MI, myocardial infarction; NSTEMI, non-ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; QCA, quantitative coronary angiography; STEMI, ST-segment-elevation myocardial infarction; and VD, vessel disease. 
Incidence and Characteristics of Angiographically Overt LSD Cases
A total of 9 cases (7 in offset peak-to-peak design [Promus Element]; 2 in peak-to-valley design [Promus or Xience V]) of angiographically overt LSD were identified ( Figure 6 ). All cases had secondary device use after index stenting. Only 1 case required additional stenting for LSD and 1 patient died of noncardiac cause during the follow-up period (Table 5) .
Discussion
This study systematically examined effects of clinical, lesion, and procedural characteristics on the occurrence of LSD in 3 different contemporary DES platforms. We also reported the incidence of LSD using quantitative methods and its longterm clinical implications. In this patient-level analysis of a multicenter second-generation pooled DES cohort composed of 7350 lesions in 5871 patients, any use of secondary device after stenting was the single most important independent factor related with QCA-based LSD, regardless of the type of stent or other lesion factors. Although the prognostic impact of QCAbased LSD on 3-year clinical outcomes was statistically insignificant, there were numerically higher rates of TLF, POCO, and any repeat revascularization in the QCA-based LSD group.
LSD Detected by Dedicated QCA Analysis
Studies are limited that report incidence of LSD evaluated in a well-established cohort. Previous studies were anecdotal, reporting only angiographically overt LSD cases, most of which occurred in the Promus Element stents. 1, 7, 16 The incidence of LSD was likely underreported given the difficulty in detecting LSD with visual examination. Although Kereiakes et al 17 performed a pooled analysis of PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) and PLATINUM trials (A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System for the Treatment of Up to Two de Novo Coronary Artery Lesions) with core laboratory QCA analysis, it failed to detect any LSD case in 2403 stents. This might be explained by the highly selected population in the trials, excluding high-risk patients and complex lesion subsets. C and D, A Xience V stent (red dotted lines, 3.0×15 mm) was deployed on the diffuse lesion in mid LAD, followed by an additional side branch ballooning for bifurcation lesion. LSD occurred after the procedure (white arrowhead), which was retrospectively detected by the quantitative coronary angiography (QCA) analysis (absolute decrease of 3.36 mm and relative decrease of 25.5%). E and F, An Endeavor Resolute stent (red dotted lines, 3.5×38 mm) was implanted in the diffuse lesion in proximal LAD, followed by the post-dilation and IVUS evaluation. An eccentric LSD occurred in the proximal edge of the implanted stent (white arrowhead), which was retrospectively detected by the QCA analysis (absolute decrease of 5.11 mm and relative decrease of 16.7%). 
Risk Factors of Longitudinal Stent Deformation
We systematically examined enriched real-world population with high-risk profiles, using a dedicated QCA analysis with prespecified definition of LSD. The angiographically overt LSD occurred in only 9 of 7350 cases (0.12%) in this study, which is concordant with the scarcity with which this phenomenon occurs in routine clinical practice. However, by uniformly measuring the stent length before, immediately after implantation, and after the final procedure, the incidence of QCA-based LSD was ≤1.12%. Such a high incidence suggests that QCA-based LSD, which can be missed by simple visual assessment, still occurs in contemporary practice. Interestingly, the angiographically overt LSD showed the highest incidence in the Promus Element stent (7 of 9 cases), but the occurrence of QCA-based LSD was not significantly different among the various type of stent platform. A quantitative definition of LSD by QCA could have detected hidden LSD cases in less radio-opaque stents, such as Xience, Resolute, or Biomatrix, which were difficult to detect via visual examination of angiography. 18 In line with these results, an IVUS analysis also reported that the incidence of LSD was similar among various types of second-generation DES. 19 These findings suggest that factors other than the stent platform itself, such as lesion or procedural factors, may have had a greater impact on the occurrence of QCA-based LSD.
Procedural Insights on the Mechanism of LSD
The multivariable analysis showed that provisional side branch stenting or ballooning, additional downstream intervention, and use of imaging device such as IVUS were independently associated with QCA-based LSD. Similar studies supporting our results have been reported. Arnous et al 4 showed that multiple stenting, and use of Guideliner, and postdilation balloon were independent predictors of LSD. In another study, LSD was significantly associated with the use of extra support guiding catheter or guidewire, or a passage of a second stent. 5 In addition, aggressive guide catheter manipulation, use of imaging devices including IVUS or optical coherence tomography, and multiple ballooning have been suggested as factors associated with LSD occurrence. 2, 3, 9, 19, 20 Our subgroup analysis also showed that any use of secondary devices was the single most important independent factor predicting QCA-based LSD, regardless of the lesion or stent factors. If the proximal portion of the stent is not completely apposed to the vessel wall, frequent use of secondary devices may increase the chance of contact with unopposed struts especially when wire bias exists resulting in the occurrence of LSD. 4 Therefore, appropriate stent sizing and apposition, especially in the proximal portion of the stent before introduction of secondary devices, may be important. Careful manipulation of procedural devices including guiding catheters, daughter-in-mother backup support catheters, IVUS, and adjunctive balloons may reduce the occurrence of LSD.
Also, stents located in the ostium or left main coronary artery are prone to LSD by longitudinal forces, because of frequent malapposition of stents by undersizing, and because of recurrent contact with the guiding catheter which goes in and out during various device insertion and pullback, especially when there is poor alignment with the coronary artery.
3,4
Clinical Implications
Although the overall impact of the QCA-based LSD on 3-year outcomes was not statistically significant, the rates of all clinical end points including TLF, POCO, and repeat revascularization were numerically higher in the QCA-based LSD group. A greater number of patients could have resulted in statistical significance. Therefore, a larger database to confirm the longterm clinical implication is needed. To date, the relationship 4, 5, 22 and these have been mostly single-center reports, did not apply any precise diagnostic criteria for LSD, and did not evaluate events beyond 1 year.
Theoretically, LSD could result in the stent malapposition, incomplete plaque coverage, and reduced drug delivery. This could lead to in-stent restenosis and stent thrombosis, 2,23 which may account for the nominally higher incidence of clinical outcomes observed in our study. Because it is difficult to detect LSD by visual estimation of angiography, there is the possibility for insufficient lesion coverage and deformed malapposed stent struts when LSD that is not angiographically overt occurs. When LSD is suspected, the confirmation of full lesion coverage and optimal stent apposition may minimize future adverse events.
Study Limitations
The study population was heterogeneous as a merged cohort composed of 2 different studies was assessed. We tried to complement the heterogeneity with comprehensive patientlevel pooling. A substantial proportion of patients who were lost to follow-up could be also a limitation of the study. However, the vital status of these patients was completely assessed as previously described. The study cohort only included 3 major stent platforms and not all of the commercially available diverse second-generation DES that are in clinical use. The effect of guiding catheters could not be assessed, as the cohorts did not clearly document the type of guiding catheters used during the procedure. Because our QCA analysis was based on the angiographic view with the most severe lumen obstruction, it has inherent limitations in assessing LSD and measuring stent lengths. And it can be assumed that true blinding would be difficult because of the morphological difference according to stent types. The lack of precise definition of stent edges and the potential for stent foreshortening in certain views could also limit the accuracy of QCA analysis. Further, the QCA analysis might be affected by the cases with severe calcification and the different visibility among various stent types. However, we carefully selected lesions which were appropriate to be analyzed and excluded cases with unreliable angiographic images including foreshortening. We also used specialized QCA technicians who were blinded to the purpose of the study, and all suspected LSD cases were reviewed by an independent group of physicians. Moreover, we think that any potential errors in measurement because of these issues would have been evenly distributed considering large number of lesions analyzed from a large cohort.
Conclusions
Although uncommon, LSD occurs in the currently used second-generation DES, regardless of the type of stent platform. Additional downstream imaging and procedures were strongly related with the LSD, independent with lesion factors or stent types. Careful manipulation of secondary imaging or procedure devices, as well as adequate stent apposition, may decrease the incidence of LSD. 
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